Cite
Lenvatinib improves anti-PD-1 therapeutic efficacy by promoting vascular normalization via the NRP-1-PDGFRβ complex in hepatocellular carcinoma
MLA
Jieying Yang, et al. “Lenvatinib Improves Anti-PD-1 Therapeutic Efficacy by Promoting Vascular Normalization via the NRP-1-PDGFRβ Complex in Hepatocellular Carcinoma.” Frontiers in Immunology, vol. 14, July 2023. EBSCOhost, https://doi.org/10.3389/fimmu.2023.1212577.
APA
Jieying Yang, Zhixing Guo, Mengjia Song, Qiuzhong Pan, Jingjing Zhao, Yue Huang, Yulong Han, Dijun Ouyang, Chaopin Yang, Hao Chen, Muping Di, Yan Tang, Qian Zhu, Qijing Wang, Yongqiang Li, Jia He, Desheng Weng, Tong Xiang, & JianChuan Xia. (2023). Lenvatinib improves anti-PD-1 therapeutic efficacy by promoting vascular normalization via the NRP-1-PDGFRβ complex in hepatocellular carcinoma. Frontiers in Immunology, 14. https://doi.org/10.3389/fimmu.2023.1212577
Chicago
Jieying Yang, Zhixing Guo, Mengjia Song, Qiuzhong Pan, Jingjing Zhao, Yue Huang, Yulong Han, et al. 2023. “Lenvatinib Improves Anti-PD-1 Therapeutic Efficacy by Promoting Vascular Normalization via the NRP-1-PDGFRβ Complex in Hepatocellular Carcinoma.” Frontiers in Immunology 14 (July). doi:10.3389/fimmu.2023.1212577.